Flashcard library · Biology · PaperFren
ATR inhibitor blocks SARS-CoV-2
DDR/ATR inhibitor berzosertib potently blocks SARS-CoV-2 replication in cell culture.
Keep what you just learned
Save these 10 cards to your NoteFren library. Your first review starts right away, and each card links back to the study it came from.
Screen size?
430 kinase inhibitors.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Top hit?
Berzosertib (ATR inhibitor).
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
100 nM result?
Complete inhibition at 48 hpi.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Cell system?
Vero E6 SARS-CoV-2 culture.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Virus isolate?
USA-WA1/2020.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Other actives named?
Torin2 and vistusertib also active.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Controls?
HQ and interferons blocked infection.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Target class?
Host DDR/ATR pathway.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Limit?
Cell culture ≠ proven clinical benefit.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified
Takeaway?
Host kinase pathways can be antiviral targets.
Source: Antiviral drug screen identifies DNA-damage response inhibitor as potent blocker of SARS-CoV-2 replication · DOI · quote verified